161 related articles for article (PubMed ID: 38829515)
1. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference.
Gupta K; Rawlley B; Meloche C; Minhas AMK; Hermel M; Slipczuk L; Sheikh S; Khoja A; Vaughan EM; Dalakoti M; Virani SS
Curr Atheroscler Rep; 2024 Jun; ():. PubMed ID: 38829515
[TBL] [Abstract][Full Text] [Related]
2. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American College of Cardiology Conference.
Gupta K; Balachandran I; Foy J; Hermel M; Latif A; Krittanawong C; Slipczuk L; Baloch F; Samad Z; Virani SS
Curr Atheroscler Rep; 2023 Jun; 25(6):309-321. PubMed ID: 37086374
[TBL] [Abstract][Full Text] [Related]
3. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
[TBL] [Abstract][Full Text] [Related]
4. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
5. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions.
Gupta K; Hirsch JR; Kalsi J; Patel V; Gad MM; Virani SS
Curr Atheroscler Rep; 2023 Jan; 25(1):31-41. PubMed ID: 36602752
[TBL] [Abstract][Full Text] [Related]
6. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
7. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
[TBL] [Abstract][Full Text] [Related]
8. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394
[TBL] [Abstract][Full Text] [Related]
9. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
Lloyd-Jones DM; Morris PB; Ballantyne CM; Birtcher KK; Daly DD; DePalma SM; Minissian MB; Orringer CE; Smith SC
J Am Coll Cardiol; 2017 Oct; 70(14):1785-1822. PubMed ID: 28886926
[TBL] [Abstract][Full Text] [Related]
10. Inclisiran: A Review in Hypercholesterolemia.
Frampton JE
Am J Cardiovasc Drugs; 2023 Mar; 23(2):219-230. PubMed ID: 36869996
[TBL] [Abstract][Full Text] [Related]
11. Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease.
Albosta MS; Grant JK; Taub P; Blumenthal RS; Martin SS; Michos ED
Vasc Health Risk Manag; 2023; 19():421-431. PubMed ID: 37434791
[TBL] [Abstract][Full Text] [Related]
12. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
13. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects.
Duprez DA; Handelsman Y; Koren M
Vasc Health Risk Manag; 2020; 16():403-418. PubMed ID: 33116551
[TBL] [Abstract][Full Text] [Related]
15. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG
Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572
[TBL] [Abstract][Full Text] [Related]
16. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Garvey WT; Mechanick JI; Brett EM; Garber AJ; Hurley DL; Jastreboff AM; Nadolsky K; Pessah-Pollack R; Plodkowski R;
Endocr Pract; 2016 Jul; 22 Suppl 3():1-203. PubMed ID: 27219496
[TBL] [Abstract][Full Text] [Related]
17. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress.
Gupta K; Hinkamp C; Andrews T; Meloche C; Minhas AMK; Slipczuk L; Vaughan E; Habib FZ; Sheikh S; Kalra D; Virani SS
Curr Atheroscler Rep; 2023 Dec; 25(12):965-978. PubMed ID: 37975955
[TBL] [Abstract][Full Text] [Related]
18. Role of Different Low-Density Lipoprotein-Lowering Medications on Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients With Diabetes Mellitus.
Saag JL; Gross D; Stirt D; Espina Rey A; Gros B
Cureus; 2023 Jun; 15(6):e40905. PubMed ID: 37492827
[TBL] [Abstract][Full Text] [Related]
19. Spotlight from the American Society for Preventive Cardiology on Key Features of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol.
Wong ND; Amsterdam EA; Ballantyne C; Khera A; Nasir K; Toth PP;
Am J Cardiovasc Drugs; 2020 Feb; 20(1):1-9. PubMed ID: 31286451
[TBL] [Abstract][Full Text] [Related]
20. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.
Imran TF; Khan AA; Has P; Jacobson A; Bogin S; Khalid M; Khan A; Kim S; Erqou S; Choudhary G; Aspry K; Wu WC
PLoS One; 2023; 18(12):e0295359. PubMed ID: 38055686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
